This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsuji, B. T.
Right arrow Articles by Sakoulas, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsuji, B. T.
Right arrow Articles by Sakoulas, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2007, p. 1089-1091, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.00671-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Evaluation of Accessory Gene Regulator (agr) Group and Function in the Proclivity towards Vancomycin Intermediate Resistance in Staphylococcus aureus{triangledown}

Brian T. Tsuji,1,2,5 Michael J. Rybak,1,2,3* Kerry L. Lau,1 and George Sakoulas4

Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences,1 School of Medicine, Wayne State University,3 Detroit Receiving Hospital and University Health Center, Detroit, Michigan 48201,2 Department of Medicine, Division of Infectious Diseases, New York Medical College, Munger Pavilion 245, Valhalla, New York, 10595,4 University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York 142605

Received 1 June 2006/ Returned for modification 15 August 2006/ Accepted 4 December 2006


arrow
ABSTRACT
 
Simulated therapeutic vancomycin exposures were evaluated against agr wild-type and knockout Staphylococcus aureus groups I, II, III, and IV using an in vitro pharmacodynamic model. All agr groups developed intermediate resistance to vancomycin after subtherapeutic exposure. The free unbound fraction of the area under the concentration-time curve (fAUC/MIC) required to suppress resistance was fourfold higher (P < 0.001) in agr dysfunctional strains (112 to 169) than that in parent wild-type strains (28).


arrow
TEXT
 
The accessory gene regulator is a quorum-sensing operon which coordinates the expression of secreted and cell-associated virulence factors and controls several metabolic pathways in Staphylococcus aureus in a growth phase-related fashion (4, 5, 7, 8). S. aureus strains which exhibit a dysfunction accessory gene regulator (agr) locus may possess an intrinsic survival advantage under vancomycin-selective pressure (11-14). However, the correlation between vancomycin exposure using the area under the concentration-time curve (AUC/MIC) necessary to suppress the development of vancomycin-intermediate resistance and agr function or group has not been investigated. We examined the relationship between vancomycin exposure and the development of intermediate-level resistance in agr groups I, II, III, and IV S. aureus using an in vitro pharmacodynamic model.

RN6390, RN6607, RN3984, and RN4850 represent agr-positive S. aureus prototype strains carrying agr groups I, II, III, and IV, respectively, and were obtained from the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA), supported under NIAID/NIH contract N01-AI-95359, and Richard P. Novick. RN6911, RN9120, and RN9121 are the agr-null derivates of groups I, II, and IV (NARSA), respectively. RN3984-M is the null derivate of RN3984, which demonstrated a loss of agr function by a lack of production of delta-hemolysin.

Vancomycin analytical-grade powder was commercially purchased (Sigma, St. Louis, MO). Stock solutions were freshly prepared at the beginning of each week and kept frozen daily at –4°C. Mueller-Hinton broth (Difco, Detroit, MI) supplemented with 25 µg/ml calcium and 12.5 µg/ml magnesium (SMHB) was used for in vitro pharmacodynamic models and susceptibility testing involving vancomycin. Colony counts were determined using tryptic soy agar (TSA; Difco, Detroit, MI) plates. MICs were determined by broth microdilution in SMHB according to CLSI guidelines (2). The function of the agr operon was qualitatively assessed in all isolates using S. aureus RN4420 (NARSA) for delta-hemolysin expression, as previously described (13).

An in vitro pharmacodynamic model was utilized as previously described for the collection of bacterial and antimicrobial dosing and sampling (1). All model simulations were conducted over 72 h and were performed in triplicate to ensure reproducibility. Vancomycin regimens of 62.5, 125, 250, 500, 750, and 1,000 mg every 12 h (free unbound fraction of the AUC [fAUC/MIC/24] exposures of 14 to 225 µg/ml/h; half-life 6 h) were simulated according to the manufacturer's recommendations for a patient with normal renal function. A protein binding level of 55% was utilized for all model simulations (9). Antibiotic concentrations were determined from each model at 0 to 72 h for pharmacokinetic analysis. The AUC from 0 to 24 h was calculated using the linear trapezoid method. Vancomycin concentrations were determined by fluorescence polarization immunoassay (TDx; Abbott Diagnostics) as previously described (16). Differences between regimens in log10 CFU/ml at 72 h were determined using analysis of variance with Tukey's test for multiple comparisons. All statistical analyses were performed using SPSS statistical software (Release 12.0; SPSS, Inc., Chicago, Illinois).

The development of resistance was evaluated at multiple time points throughout the simulation at 0, 24, 48, and 72 h for all model simulations. Resistance was determined by the detection of growth on TSA plates containing 3 and 6 µg/ml and by changes in MIC via Etest of all model samples.

All of the characterized S. aureus strains evaluated were susceptible to vancomycin MICs of 1.0 µg/ml. Observed pharmacokinetic parameters for all tested therapeutic regimens are shown in Table 1. Quantitative changes in log10 CFU/ml over 72 h are graphically displayed in Fig. 1. Changes in MIC secondary to 72 h vancomycin exposure are displayed in Table 2. Against all agr-null strains (agr group I, II, III, and IV), the exposure of an fAUC/MIC of 14 resulted in a subsequent increase in MIC at 72 h. In agr-null group II, S. aureus increases to a MIC of 8 µg/ml were noted secondary to exposure as high as an fAUC/MIC of 112. Parent wild-type strains (agr groups I, II, III, and IV [RN6390, RN6607, RN3984, and RN8450, respectively]) also resulted in the development of intermediate resistance after exposure to an fAUC/MIC of 14, although the magnitude of MIC increases were lower compared with that in agr-null isolates: MIC increases of 3 to 4 µg/ml were noted in agr-positive isolates relative to increases of 6 to 8 µg/ml in agr-null isolates. The vancomycin exposure necessary to suppress the development of resistance in S. aureus agr knockout isolates was fourfold greater with fAUC/MICs of 112 to 169 versus an fAUC/MIC of 28 for wild-type, agr-positive isolates (P < 0.001).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Pharmacokinetic and pharmacodynamic parameters obtained with in vitro modelsa


Figure 1
View larger version (18K):
[in this window]
[in a new window]

  		FIG. 1. Representative activity of vancomycin at simulated regimens over 72 h against agr group II (RN6607 agr II wild type and the null derivate RN9120). Error bars indicate standard deviations.


View this table:
[in this window]
[in a new window]

  		TABLE 2. Vancomycin MIC over 72 h secondary to varying fAUC/MIC exposures

Recently, prolonged administration of vancomycin has been linked with vancomycin tolerance and down-regulation of the agr locus. In addition, S. aureus exposure to trough vancomycin concentrations of <10 µg/ml has been associated with an increase in the MIC and development of glycopeptide-intermediate S. aureus-like characteristics (15a, 17). In the present investigation, we sought to determine whether a relationship exists between the development of heterogeneous resistance among all wild-type and knockout agr isolates using an in vitro pharmacodynamic model simulating vancomcyin therapeutic dosing. S. aureus isolates that were dysfunctional in agr required vancomycin doses and fAUC/MICs more than fourfold higher than that necessary for wild-type isolates to prevent the development of resistance. Interestingly, although we observed MIC increases of up to 3 to 4 µg/ml (which may be currently classified as reduced susceptibility) in wild-type, agr-positive isolates, the alterations in MIC in agr dysfunctional isolates were typically at least onefold higher at 6 to 8 µg/ml at the same vancomycin exposure. Therefore, in all agr dysfunctional isolates, the development of intermediate resistance was evident after subtherapeutic vancomycin exposure using both the previous (≤4 µg/ml) and newer breakpoints of susceptibility (≤2 µg/ml) (2). Additionally, although we found the development of resistance in all agr dysfunctional groups, the magnitude of increase in vancomycin MIC was greatest in the agr-null group II isolate. This is in agreement with previous reports that this genotype may possess an intrinsic survival advantage (6, 15), as this isolate demonstrated the largest increase in MIC (8 µg/ml), and the greatest exposure of vancomycin was necessary to suppress the development of resistance.

We conclude that the development of vancomycin-intermediate resistance may be driven by suboptimal vancomycin exposure in the setting of dysfunction in the agr locus in S. aureus. These findings suggest the use of more aggressive vancomycin-dosing strategies to maintain optimal exposures. These findings highlight the potential problems associated with suboptimal vancomycin exposures, which ultimately impact the susceptibility of this antibiotic with possible consequences to other classes of antimicrobials (3, 10, 11, 17). More attention to optimal dosing of vancomycin may be important in managing methicillin-resistant Staphylococcus aureus infections.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Anti-Infective Research Laboratory, Pharmacy Practice - 4148, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201. Phone: (313) 993-4673. Fax: (313) 577-8915. E-mail: m.rybak{at}wayne.edu. Back

{triangledown} Published ahead of print on 11 December 2006. Back


arrow
REFERENCES
 
    1
  1. Allen, G. P., R. Cha, and M. J. Rybak. 2002. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 46:2606-2612.[Abstract/Free Full Text]
    2. 2
  2. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
    3. 3
  3. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.[Abstract/Free Full Text]
    4. 4
  4. Ji, G., R. Beavis, and R. P. Novick. 1997. Bacterial interference caused by autoinducing peptide variants. Science 276:2027-2030.[Abstract/Free Full Text]
    5. 5
  5. Lyon, G. J., J. S. Wright, T. W. Muir, and R. P. Novick. 2002. Key determinants of receptor activation in the agr autoinducing peptides of Staphylococcus aureus. Biochemistry 41:10095-10104.[CrossRef][Medline]
    6. 6
  6. Moise-Broder, P. A., G. Sakoulas, G. M. Eliopoulos, J. J. Schentag, A. Forrest, and R. C. Moellering, Jr. 2004. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38:1700-1705.[CrossRef][Medline]
    7. 7
  7. Novick, R. P. 2003. Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol. Microbiol. 48:1429-1449.[CrossRef][Medline]
    8. 8
  8. Novick, R. P. 2000. Pathogenicity factors and their regulation, p. 392-407. In V. A. Fischetti, R. P. Novick, J. J. Ferretti, and D. A. Portnoy (ed.), Gram-positive pathogens. American Society for Microbiology, Washington, DC.
    9. 9
  9. Rybak, M. J. 2006. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42(Suppl. 1):S35-S39.
    10. 10
  10. Sakoulas, G., J. Alder, C. Thauvin-Eliopoulos, R. C. Moellering, Jr., and G. M. Eliopoulos. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585.[Abstract/Free Full Text]
    11. 11
  11. Sakoulas, G., G. M. Eliopoulos, V. G. Fowler, Jr., R. C. Moellering, Jr., R. P. Novick, N. Lucindo, M. R. Yeaman, and A. S. Bayer. 2005. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob. Agents Chemother. 49:2687-2692.[Abstract/Free Full Text]
    12. 12
  12. Sakoulas, G., G. M. Eliopoulos, R. C. Moellering, Jr., R. P. Novick, L. Venkataraman, C. Wennersten, P. C. DeGirolami, M. J. Schwaber, and H. S. Gold. 2003. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J. Infect. Dis. 187:929-938.[CrossRef][Medline]
    13. 13
  13. Sakoulas, G., G. M. Eliopoulos, R. C. Moellering, Jr., C. Wennersten, L. Venkataraman, R. P. Novick, and H. S. Gold. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492-1502.[Abstract/Free Full Text]
    14. 14
  14. Sakoulas, G., R. C. Moellering, Jr., and G. M. Eliopoulos. 2006. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin. Infect. Dis. 42(Suppl. 1):S40-S50.
    15. 15
  15. Sakoulas, G., P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, Jr., and G. M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.[Abstract/Free Full Text]
    16. 15
  16. Sakoulas, G., H. S. Gold, R. A. Cohen, L. Venkataraman, R. C. Moellering, and G. M. Eliopoulos. 2006. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J. Antimicrob. Chemother. 57:699-704.[Abstract/Free Full Text]
    17. 16
  17. Tsuji, B. T., and M. J. Rybak. 2005. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 49:2735-2745.[Abstract/Free Full Text]
    18. 17
  18. Woods, C. W., A. C. Cheng, V. G. Fowler, Jr., M. Moorefield, J. Frederick, G. Sakoulas, V. G. Meka, F. C. Tenover, P. Zwadyk, and K. H. Wilson. 2004. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. 38:1188-1191.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, March 2007, p. 1089-1091, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.00671-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sun, W., Chen, H., Liu, Y., Zhao, C., Nichols, W. W., Chen, M., Zhang, J., Ma, Y., Wang, H. (2009). Prevalence and Characterization of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates from 14 Cities in China. Antimicrob. Agents Chemother. 53: 3642-3649 [Abstract] [Full Text]  
  • Harigaya, Y., Bulitta, J. B., Forrest, A., Sakoulas, G., Lesse, A. J., Mylotte, J. M., Tsuji, B. T. (2009). Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia. Antimicrob. Agents Chemother. 53: 3894-3901 [Abstract] [Full Text]  
  • Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R. Jr., Craig, W., Billeter, M., Dalovisio, J. R., Levine, D. P. (2009). Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82-98 [Full Text]  
  • Lodise, T. P., Lomaestro, B., Graves, J., Drusano, G. L. (2008). Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity. Antimicrob. Agents Chemother. 52: 1330-1336 [Abstract] [Full Text]  
  • Tsuji, B. T., von Eiff, C., Kelchlin, P. A., Forrest, A., Smith, P. F. (2008). Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype. Antimicrob. Agents Chemother. 52: 1533-1537 [Abstract] [Full Text]  
  • Rose, W. E., Rybak, M. J., Tsuji, B. T., Kaatz, G. W., Sakoulas, G. (2007). Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function. J Antimicrob Chemother 59: 1190-1193 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsuji, B. T.
Right arrow Articles by Sakoulas, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsuji, B. T.
Right arrow Articles by Sakoulas, G.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»